Posts Tagged: plasma

Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →


Leading Innovation in Biomarker Testing: Liquid Biopsy

Cutting edge approaches which use techniques such as liquid biopsy are the future of biomarker testing, but require expertise and leadership to develop. QIAGEN’s companion diagnostic assays are designed to ease the challenges faced by pathologists in labs performing the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to… Read article →


Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →